KiteLock 4%
Commercial- Indications
- Catheter-related bloodstream infections, Catheter occlusions
Company intelligence / Profile preview
SterileCare’s lead product KiteLock 4% is a non-antibiotic catheter lock solution clinically proven to reduce central line-associated bloodstream infections and catheter occlusions by over 70%. It is the only globally approved lock solution safe enough for children. A pivotal clinical trial is ongoing at Cincinnati Children’s Hospital to evaluate its safety and effectiveness versus standard heparin locks in preventing CVC occlusions among pediatric patients with intestinal failure. As of January 2025, the study had enrolled 20 of a planned 124 participants
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on SterileCare.